XTL BIOPHARMACEUTICALS-ADR (XTLB) Stock Price & Overview
NASDAQ:XTLB • US98386D3070
Current stock price
The current stock price of XTLB is 2.48 USD. Today XTLB is up by 5.98%. In the past month the price decreased by -4.6%. In the past year, price decreased by -44.89%.
XTLB Key Statistics
- Market Cap
- 23.467M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
XTLB Stock Performance
XTLB Stock Chart
XTLB Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to XTLB. When comparing the yearly performance of all stocks, XTLB is a bad performer in the overall market: 87.82% of all stocks are doing better.
XTLB Earnings
XTLB Forecast & Estimates
XTLB Groups
Sector & Classification
XTLB Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
XTLB Ownership
XTLB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.31 | 375.559B | ||
| AMGN | AMGEN INC | 15.58 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 16.07 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.05 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.42 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.06 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 11.02 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.24 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.66 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XTLB
Company Profile
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
Company Info
IPO: 2000-09-01
XTL BIOPHARMACEUTICALS-ADR
5 Badner St., P.O.Box 8241
Ramat Gan 4365603 IL
CEO: Shlomo Shalev
Employees: 33
Phone: 97299557080
XTL BIOPHARMACEUTICALS-ADR / XTLB FAQ
What does XTLB do?
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
Can you provide the latest stock price for XTL BIOPHARMACEUTICALS-ADR?
The current stock price of XTLB is 2.48 USD. The price increased by 5.98% in the last trading session.
Does XTL BIOPHARMACEUTICALS-ADR pay dividends?
XTLB does not pay a dividend.
What is the ChartMill rating of XTL BIOPHARMACEUTICALS-ADR stock?
XTLB has a ChartMill Technical rating of 0 out of 10.You can find more details on the Technical Analysis and Fundamental Analysis tabs.
What is the employee count for XTLB stock?
XTL BIOPHARMACEUTICALS-ADR (XTLB) currently has 33 employees.